Heaith Economics Evaluation And Policy Research On Program Of Early Diagnosis And Treatment Of Esophageal Cancer In Linzhou

BackgroundThe mortality rate of esophageal cancer in Henan Province is the highest in China, which is31.71per100,000people in1984～2002. Things are much worse in Linzhou County, the mortality rate of which is102.10per100,000people,69.83per100,000people,61.73per100,000people,55.27per100,000people in1984～1988,1989～1993,1994～1998and1999～2002, respectively.To promote the program of early diagnosis and treatment of esophageal cancer in other districts, the program should not only be evidence-based, but also have a good cost-benefit ratio and corresponding policy. Therefore, it is necessary to analyze the cost-benefit and related policy.ObjectiveTo sum up the practice and research experiences, to analyze cost-benefit and policy of the program of early diagnosis and treatment of esophageal cancer in Linzhou County, and to provide policy advise for further health reforms and development.MethodsCombining the literature review and field data in Linzhou, a comprehensive analysis is made based on these data. Through these data and analysis, the economic evaluation and related policy research is made.Main Results1. The central government has put a total2,632,992RMB into this program in2005～2010, which is greater in recent years but still not much.2. The patients diagnosed in early phase of esophageal and gastric cancer is71and76respectively in2005～2010. There are only54and52of them who received medical treatment.3. The total benefits of the program in Linzhou is5,043,634RMB in2005～2009, of which the benefits of esophageal cancer solo is2,985,060RMB and the benefits of precancerous lesion group is1,787,357RMB.4. The screening cost of every patient with precancerous lesion is781.8RMB, every patient with early phase cancer is15107.1RMB, every patient with advanced cancer is68485.3RMB, every patient with carcinoma in situ and above is4447.1RMB, and every people participating is198.9RMB.5. The cost-benefit ratio is1:2.45, which is increased from1:1.45by joint screening of gastric cancer and is increased from1:1.58by proper follow-up of precancerous lesion group.